- Reuters•30 minutes ago
Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. As a result, the U.S. biotechnology company said it would not seek an additional approval for Revlimid for that use, and its shares fell more than 2 percent. Revlimid, a multiple myeloma treatment with annual sales of about $6 billion, was being tested versus a placebo in patients whose diffuse large B-cell lymphoma had responded to initial treatment with Roche's Rituxan and chemotherapy.
- TheStreet.com•55 minutes ago
Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.
After hours: 104.56-3.37 (-3.12%) as of 5:57 PM EDT
|Bid||104.52 x 100|
|Ask||104.60 x 200|
|52wk Range||92.98 - 136.40|
|Day's Range||106.73 - 108.14|
|Avg Vol (3m)||4,365,147|
As of 4:00 PM EDT. Market closed.